Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer

References

• Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and –2. J Biol Chem 1996; 271: 33157–60
   PubMed Web of Science ®Google Scholar
• Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997; 113: 1999–03
   PubMedGoogle Scholar
• Subbaramaiah K, Telang N, Ramonetti JT, Araki R, Devito B, Weksler BB, et al. Transcription of cyclooxygenase-2 enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 4424–9
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9
   PubMed Web of Science ®Google Scholar
• Rajnakova A, Moochhala S, Goh PM, Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001; 172: 177–85
   PubMed Web of Science ®Google Scholar
• Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003; 7: 207–22
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Dubois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B. Cancer Res 2001; 61: 2670–5
   PubMed Web of Science ®Google Scholar
• Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, et al. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 2000; 60: 6607–10
   PubMedGoogle Scholar
• Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS, Hsu HC. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 2004; 91: 355–61
   PubMedGoogle Scholar
• Maciag A, Sithanandam G, Anderson LM. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis 2004; 25: 2231–7
   PubMedGoogle Scholar
• Sung JJY, Leung WK, Go MYY, To KF, Cheng ASL, Ng EKW, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 729–35
   PubMed Web of Science ®Google Scholar
• Uefuji K, IchiKura T, Mochizuki H. Expression of cyclooxygenase2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001; 76: 26–30
   PubMed Web of Science ®Google Scholar
• Kawabe A, Shimade Y, Uchida S, Maeda M, Yamasaki S, Kato M, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002; 80: 79–88
   PubMedGoogle Scholar
• Van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GNJ, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196: 171–9
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–40
   PubMed Web of Science ®Google Scholar
• Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma:well versus poorly differentiated type. Cancer 2000; 89: 1418–24
   PubMed Web of Science ®Google Scholar
• Xue YW, Zhang QF, Zhu ZB, Wang Q, Fu SB. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. Would J Gastroenterol 2003; 9: 250–3
   PubMedGoogle Scholar
• Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tasunozaki H, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876–81
   PubMed Web of Science ®Google Scholar
• Lee TL, Leung WK, Lau JYW, Tong JHM, Ng KW, Chan FKL, et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Letters 2001; 168: 133–40
   PubMedGoogle Scholar
• Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, et al. Transforming growth factor-batal enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000; 275: 6628–35
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, Zweitel BS, Settle SG, Woerner BM, et al. Antiangioginic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11
   PubMed Web of Science ®Google Scholar
• Qadri SSA, Wang JH, Redmond KC, O'Donnell AF, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg 2002; 74: 1648–52
   PubMedGoogle Scholar
• Sheehan KM, Sheehan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald D, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. J Am Med Assoc 1999; 282: 1254–7
   PubMed Web of Science ®Google Scholar